Macro Group Pharmaceutical S.A.E. (Macro Capital) is specialized in developing, manufacturing and marketing pharmaceuticals. The company's products include anti-scar, skincare, antiseptic, hair care, oral care and muscle relaxant medicines. In addition, the group offers plant-based medicines. At the end of 2021, Macro Group Pharmaceutical S.A.E. (Macro Capital) had one production site in Egypt.

Employees

Sector

Pharmaceuticals

More about the company

Quotes

Date	Price	Change	Volume
11/06/26	1.210 £	0.00%	25,135,000
10/06/26	1.210 £	-4.72%	36,618,700
09/06/26	1.270 £	+0.79%	16,031,054
08/06/26	1.260 £	-1.56%	53,746,932
07/06/26	1.280 £	0.00%	31,887,071

End-of-day quote Egyptian Exchange

More quotes

Income Statement and Estimates

More financial data

End-of-day quote Egyptian Exchange Other stock markets 11/06/2026			5-day change	1st Jan Change
1.210 ^EGP	0.00%		-5.47%	+6.14%

05-17	Macro Group Pharmaceutical Q1 consol profit egp 33.3 million	RE
02-19	Macro Group Pharmaceuticals (Macro Capital) S.A.E Reports Earnings Results for the Full Year Ended December 31, 2025	CI

Market Cap	690M 13.27M 11.51M 10.61M 9.95M 18.58M 1.27B 18.97M 127M 49.02M 612M 49.81M 48.74M 2.13B	P/E Ratio 2024	-33.1x	P/E Ratio 2025	5.7x
Enterprise Value	847M 16.3M 14.14M 13.04M 12.21M 22.82M 1.56B 23.3M 155M 60.2M 752M 61.17M 59.85M 2.62B	EV / Sales 2024	3.03x	EV / Sales 2025	0.9x
Free-Float	95.08%	Yield 2024 *	-	Yield 2025	-

05-17	Macro Group Pharmaceutical Q1 consol profit egp 33.3 million	RE
02-19	Macro Group Pharmaceuticals (Macro Capital) S.A.E Reports Earnings Results for the Full Year Ended December 31, 2025	CI
02-19	Macro Group Pharmaceutical FY consol profit EGP 115.7 mln	RE
11-19	Macro Group Pharmaceuticals (Macro Capital) S.A.E Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
11-13	Macro Group Pharmaceutical nine-month consol loss EGP 66.1 million	RE
12/10/25	Macro Group Pharmaceutical shareholders approve authorized capital increase to EGP 3 billion	RE
21/08/25	Macro Group Pharmaceuticals (Macro Capital) S.A.E Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
21/08/25	Macro Group Pharmaceutical posts Q2 consol profit EGP 46.5 mln	RE
21/08/25	Macro Group Pharmaceutical board approves renewal of EGP 100 mln short-term financing from KFH	RE
22/07/25	Macro Group Pharmaceutical board proposes capital increase	RE
10/06/25	Macro Group Pharmaceuticals (Macro Capital) S.A.E Reports Earnings Results for the First Quarter Ended March 31, 2025	CI
10/04/25	MACRO Group Pharmaceutical's 328.6 Million Shares Block Traded For EGP 631 Million - EGX	RE
26/02/25	Macro Group Pharmaceuticals (Macro Capital) S.A.E Reports Earnings Results for the Full Year Ended December 31, 2024	CI

1 week	-5.47%
Current month	-3.20%
1 month	-4.72%
3 months	-12.32%
6 months	+6.14%
Current year	+6.14%

Macro Group Pharmaceuticals (Macro Capital) S.A.E Stock

Stocks

MCRO

EGS7D971C011

Pharmaceuticals

Valuation: Macro Group Pharmaceuticals (Macro Capital) S.A.E

Chart: Macro Group Pharmaceuticals (Macro Capital) S.A.E

Latest news : Macro Group Pharmaceuticals (Macro Capital) S.A.E

Quotes and Performance

Course Extremes

Managers and Directors: Macro Group Pharmaceuticals (Macro Capital) S.A.E

Other Pharmaceuticals

Financials

Company Profile

Quotes

Income Statement and Estimates

1 week	1.2	1.3
1 month	1.2	1.33
Current year	1.02	1.68
1 year	0.81	4.11
3 years	0.81	4.11
5 years	0.81	5.28
10 years	0.81	5.28

Manager	Title	Age	Since
Khaled Kamel CEO	Chief Executive Officer	-	-
Zeina Shahin IRC	Investor Relations Contact	-	-
Tamer Raouf SAM	Sales & Marketing	-	01/01/2022

Director	Title	Age	Since
Sahar El-Sallab BRD	Director/Board Member	-	01/01/2021
Ahmed Badreldin BRD	Director/Board Member	54	01/01/2021
Ahmed El-Nayeb CHM	Chairman	-	01/01/2002

	2024	2025
Net sales	520M 10M 8.68M 8M 7.5M 14M 957M 14.3M 95.42M 36.94M 462M 37.54M 36.73M 1.6B	895M 17.2M 14.93M 13.76M 12.89M 24.09M 1.65B 24.59M 164M 63.56M 794M 64.58M 63.19M 2.76B
Net income	-38.1M -733K -636K -586K -549K -1.03M -70.16M -1.05M -6.99M -2.71M -33.82M -2.75M -2.69M -118M	116M 2.23M 1.93M 1.78M 1.67M 3.12M 213M 3.18M 21.24M 8.22M 103M 8.35M 8.17M 357M
Net Debt	254M 4.88M 4.24M 3.91M 3.66M 6.84M 468M 6.98M 46.61M 18.04M 225M 18.34M 17.94M 784M	157M 3.03M 2.63M 2.42M 2.27M 4.24M 290M 4.33M 28.88M 11.18M 140M 11.36M 11.12M 486M

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
MACRO GROUP PHARMACEUTICALS (MACRO CAPITAL) S.A.E	0.00%	-5.47%	-46.93%	-59.67%	13.27M
ELI LILLY AND COMPANY	+2.16%	+3.17%	+43.57%	+160.28%	1,035B
JOHNSON & JOHNSON	-0.07%	+4.45%	+53.50%	+48.95%	574B
ABBVIE INC.	-0.08%	-0.08%	+17.37%	+62.66%	397B
ROCHE HOLDING AG	+0.37%	+0.77%	+21.19%	+15.95%	324B
ASTRAZENECA PLC	+0.10%	-2.12%	+22.97%	+14.66%	281B
NOVARTIS AG	+0.58%	+3.44%	+24.44%	+34.35%	278B
NOVO NORDISK A/S	-0.23%	+3.64%	-45.70%	-48.46%	193B
AMGEN INC.	+4.84%	+2.45%	+21.33%	+61.85%	191B
GILEAD SCIENCES, INC.	+3.61%	-2.56%	+15.16%	+61.12%	156B
Average	+0.41%	+0.97%	+12.69%	+35.17%	342.99B
Weighted average by Cap.	+0.10%	+2.39%	+29.29%	+72.82%